AbCellera Biologics (ABCL) Cash from Operations (2020 - 2026)
AbCellera Biologics (ABCL) reported Cash from Operations of 33523000.0 for Q1 2026, down 190.14% on a YoY basis from 37189125.49 in Q1 2025, and up 3.51% quarter-over-quarter from 34743000.0 in Q4 2025.
AbCellera Biologics (ABCL) Cash from Operations (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported Cash from Operations for 7 years, with the latest figure at 33523000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 190.14% year-over-year to 33523000.0; the trailing twelve-month figure through Mar 2026 stood at 153264000.0 (down 95.48% YoY), and the FY2025 full-year result was 131295000.0, down 20.95% from the prior year.
- Cash from Operations for Q1 2026 stood at 33523000.0, up from 34743000.0 in the prior quarter.
- The five-year high for Cash from Operations was 273015000.0 in Q2 2022, with the low at 126786000.0 in Q3 2022.
- Historically, Cash from Operations has averaged 2346529.41 across 5 years, with a median of 28882000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 284.97% — and 2024, when it plunged 27147.17%.
- AbCellera Biologics' Cash from Operations stood at 30912000.0 in 2022, then tumbled by 163.44% to 19611000.0 in 2023, then soared by 59.21% to 8000000.0 in 2024, then plunged by 334.29% to 34743000.0 in 2025, then advanced by 3.51% to 33523000.0 in 2026.
- The last three Cash from Operations figures came in at 33523000.0 (Q1 2026), 34743000.0 (Q4 2025), and 52594000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - | -33.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.52 Mn |
| Mar 31, 2026 | -33.52 Mn |
| Dec 31, 2025 | -34.74 Mn |
| Dec 31, 2025 | -34.74 Mn |
| Sep 30, 2025 | -52.59 Mn |
| Sep 30, 2025 | -52.59 Mn |
| Jun 30, 2025 | -32.40 Mn |
| Jun 30, 2025 | -32.40 Mn |
| Mar 31, 2025 | -11.55 Mn |
| Mar 31, 2025 | -11.55 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Sep 30, 2024 | -28.88 Mn |
| Sep 30, 2024 | -28.88 Mn |
| Jun 30, 2024 | -29.97 Mn |
| Jun 30, 2024 | -29.97 Mn |
| Mar 31, 2024 | -41.71 Mn |
| Mar 31, 2024 | -41.71 Mn |
| Dec 31, 2023 | -19.61 Mn |
| Dec 31, 2023 | -19.61 Mn |